By dissociated pre-bound IgE from FcεRI, omalizumab reduces activation of mast cells and basophils (143) – a suspected mechanism of fibrosis in IgG4-RD. This evidence concerns the gene IGHE and immunoglobulin G4-related sclerosing disease.